Tweets
Abatacept Misses on Shingrix Response
Dr. David Liew discusses abstract POS0620 at Eular 2024 in Vienna, Austria.
https://t.co/3Tp777HVTD https://t.co/PRrjm65nFK
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
"AMPLIFIED study:
abatacept vs adalimumab in RF+ACPA+ early RA
Not a single blink of difference.
Maybe for high CCP titre but the inverse for low CCP.
Sadly, theoretical mechanistic benefit doesn’t always wash out. We’ll keep on looking for predictors #EULAR2024 OP0007
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
EUSTAr study of 4431 systemic sclerosis (SSc) pts - anti-SSA antibodies are detected in 15% of SSc-patients and represent an independent risk factor for the presence of lung fibrosis (OR 1.24) & more severe lung involvement. #EULA2024 OP0013 https://t.co/oW6NBjIG7E https://t.co/toyvHxJlr9
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Shingrix in upadacitinib + MTX RA, in SELECT-COMPARE RCT:
data now out to 60w
good humoral and cellular response in most, even without MTX withheld
(& good safety too)
Important for our JAKi-treated patients to get the protection they need #EULAR2024 OP0020
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
EULAR 2024 Rheumatology Roundup
Featuring Drs. Artie Kavanaugh and Jack Cush Discussion of highlights from the EULAR 2024 Meeting in Vienna
https://t.co/TqEAuk0PGp https://t.co/erRZ3cLxhu
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
SpA patients with IBD, compared to those without IBD, were less frequently male and more frequently HLA-B27 negative, had higher rates of uveitis and lower rates of psoriasis, exhibited more structural damage on SI joints in the METEOR cohort #EULAR2024 OP0085
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
PsA: Switch or Cycle, the Eternal Question
Dr. Aurelie Najm reports on abstracts POS0278 and POS0266 presented at Eular 2024 in Vienna, Austria.
https://t.co/xA8YYCi94r https://t.co/RyS6vnlzam
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
lanalumab (anti-baff) LTE 1/3 to 1/2 LLDAS/DORIS remission at 52 wks, reduction autoabs etc - looking very promising @rheumnow #EULAR2024
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Moonlake has announced its phase 3 program to develop Sonelokimab (M1095) a dual inhibitor of IL-17A & IL-17F for use in Psoriatic arthritis. IZAR-1 & IZAR-2 Ph 3 DBPCT will enroll 1,500 adults w/ active PsA, w/ ACR 50 endpoint at Week 16 https://t.co/NUZ3cc4bUx https://t.co/nGP10y3Kuw
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
BiTEs (Bispecific T cell engagers) kill B cells by engaging T cells. IV blinatumomab (CD19xCD3 BiTE) rx of 6 refractory RA pts, led to B & T cell depletion, rapid decline Dz activity, synovitis, autoAbs & was safe, w/ brief temp & ^CrP w/ 1st rx https://t.co/ebLsknirtQ https://t.co/eEIch4g0I1
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
9 new MOAs in SLE to review - anti-cd38, cd40, ubiquitin ligase, tyk2, toll 7/8, baff-r, blyss/april, CAR-T, glycosylated cd20 @rheumnow #EULAR2024
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
Tapering Treatment for Lupus
Dr. Andrea Fava at Eular 2024 in Vienna, Austria, shares his perspectives on several sessions that addressed tapering treatment in lupus.
https://t.co/ijy5OwIoCe https://t.co/7yQIxW70Zd
Dr. John Cush @RheumNow ( View Tweet )
1 year 7 months ago
